Literature DB >> 9712802

Role of immunoglobulin A monoclonal antibodies against P23 in controlling murine Cryptosporidium parvum infection.

F J Enriquez1, M W Riggs.   

Abstract

Cryptosporidium parvum is an important diarrhea-causing protozoan parasite of immunocompetent and immunocompromised hosts. Immunoglobulin A (IgA) has been implicated in resistance to mucosal infections with bacteria, viruses, and parasites, but little is known about the role of IgA in the control of C. parvum infection. We assessed the role of IgA during C. parvum infection in neonatal mice. IgA-secreting hybridomas were developed by using Peyer's patch lymphocytes from BALB/c mice which had been orally inoculated with viable C. parvum oocysts. Six monoclonal antibodies (MAbs) were selected for further study based on indirect immunofluorescence assay reactivity with sporozoite and merozoite pellicles and the antigen (Ag) deposited on glass substrate by gliding sporozoites. Each MAb was secreted in dimeric form and recognized a 23-kDa sporozoite Ag in Western immunoblots. The Ag recognized comigrated in sodium dodecyl sulfate-polyacrylamide gel electrophoresis with P23, a previously defined neutralization-sensitive zoite pellicle Ag. MAbs were evaluated for prophylactic or therapeutic efficacy against C. parvum, singly and in combinations, in neonatal BALB/c mice. A combination of two MAbs given prophylactically prior to and 12 h following oocyst challenge reduced the number of intestinal parasites scored histologically by 21.1% compared to the numbers in mice given an isotype-matched control MAb (P < 0.01). Individual MAbs given therapeutically in nine doses over a 96-h period following oocyst challenge increased efficacy against C. parvum infection. Four MAbs given therapeutically each reduced intestinal infection 34.4 to 42.2% compared to isotype-matched control MAb-treated mice (P < 0.05). One MAb reduced infection 63.3 and 72. 7% in replicate experiments compared to isotype-matched control MAb-treated mice (P < 0.0001). We conclude that IgA MAbs directed to neutralization-sensitive P23 epitopes may have utility in passive immunization against murine C. parvum infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712802      PMCID: PMC108540          DOI: 10.1128/IAI.66.9.4469-4473.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Remission of diarrhoea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum.

Authors:  S Tzipori; D Roberton; C Chapman
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-15

2.  A cloned gene of Cryptosporidium parvum encodes neutralization-sensitive epitopes.

Authors:  L E Perryman; D P Jasmer; M W Riggs; S G Bohnet; T C McGuire; M J Arrowood
Journal:  Mol Biochem Parasitol       Date:  1996-10-01       Impact factor: 1.759

3.  Passive transfer of local immunity to influenza virus infection by IgA antibody.

Authors:  K B Renegar; P A Small
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

Review 4.  Human immunodeficiency virus infection and cryptosporidiosis: protective immune responses.

Authors:  T P Flanigan
Journal:  Am J Trop Med Hyg       Date:  1994       Impact factor: 2.345

5.  Kinetics of Cryptosporidium parvum sporozoite neutralization by monoclonal antibodies, immune bovine serum, and immune bovine colostrum.

Authors:  L E Perryman; M W Riggs; P H Mason; R Fayer
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

6.  The natural history of cryptosporidial diarrhoea in HIV-infected patients.

Authors:  I McGowan; A S Hawkins; I V Weller
Journal:  AIDS       Date:  1993-03       Impact factor: 4.177

7.  Antigens of Cryptosporidium sporozoites recognized by immune sera of infected animals and humans.

Authors:  J R Mead; M J Arrowood; C R Sterling
Journal:  J Parasitol       Date:  1988-02       Impact factor: 1.276

8.  Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity.

Authors:  J W Burns; M Siadat-Pajouh; A A Krishnaney; H B Greenberg
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

9.  Cryptosporidiosis in the acquired immunodeficiency syndrome: a study of 15 autopsy cases.

Authors:  T A Godwin
Journal:  Hum Pathol       Date:  1991-12       Impact factor: 3.466

10.  Immunotherapy of cryptosporidiosis in immunodeficient animal models.

Authors:  L E Perryman; J M Bjorneby
Journal:  J Protozool       Date:  1991 Nov-Dec
View more
  14 in total

1.  Systemic antibody responses to the immunodominant p23 antigen and p23 polymorphisms in children with cryptosporidiosis in Bangladesh.

Authors:  Anoli J Borad; Geneve M Allison; David Wang; Sabeena Ahmed; Mohammad M Karim; Anne V Kane; Joy Moy; Patricia L Hibberd; Sitara Swarna Rao Ajjampur; Gagandeep Kang; Stephen B Calderwood; Edward T Ryan; Elena Naumova; Wasif A Khan; Honorine D Ward
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

2.  Obtaining hyperimmune anti-Cryptosporidium parvum ovine colostrum. A study of the humoral immune response in immunized sheep.

Authors:  S Martín-Gómez; M A Alvarez-Sánchez; F A Rojo-Vázquez
Journal:  Parasitol Res       Date:  2005-11-16       Impact factor: 2.289

3.  Cloning and sequence analysis of a highly polymorphic Cryptosporidium parvum gene encoding a 60-kilodalton glycoprotein and characterization of its 15- and 45-kilodalton zoite surface antigen products.

Authors:  W B Strong; J Gut; R G Nelson
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

4.  Cloning and expression of a DNA sequence encoding a 41-kilodalton Cryptosporidium parvum oocyst wall protein.

Authors:  M C Jenkins; J Trout; C Murphy; J A Harp; J Higgins; W Wergin; R Fayer
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

5.  Cryptosporidiosis in HIV/AIDS patients in Kenya: clinical features, epidemiology, molecular characterization and antibody responses.

Authors:  Jane W Wanyiri; Henry Kanyi; Samuel Maina; David E Wang; Aaron Steen; Paul Ngugi; Timothy Kamau; Tabitha Waithera; Roberta O'Connor; Kimani Gachuhi; Claire N Wamae; Mkaya Mwamburi; Honorine D Ward
Journal:  Am J Trop Med Hyg       Date:  2014-05-27       Impact factor: 2.345

6.  Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis.

Authors:  Michael W Riggs; Deborah A Schaefer; Sushila J Kapil; Lise Barley-Maloney; Lance E Perryman
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

7.  Evidence of thymus-independent local and systemic antibody responses to Cryptosporidium parvum infection in nude mice.

Authors:  A A Adjei; J T Jones; M W Riggs; F J Enriquez
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

8.  Fecal antibodies to Cryptosporidium parvum in healthy volunteers.

Authors:  S M Dann; P C Okhuysen; B M Salameh; H L DuPont; C L Chappell
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

9.  Characterization and formulation of multiple epitope-specific neutralizing monoclonal antibodies for passive immunization against cryptosporidiosis.

Authors:  D A Schaefer; B A Auerbach-Dixon; M W Riggs
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

10.  Cryptosporidium parvum sporozoite pellicle antigen recognized by a neutralizing monoclonal antibody is a beta-mannosylated glycolipid.

Authors:  M W Riggs; M R McNeil; L E Perryman; A L Stone; M S Scherman; R M O'Connor
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.